



# WORKPLAN

<b>Angus PMG</b>				<b>Agenda Item:</b>
<b>Date of Meeting:</b>	240821	<b>Version No.</b>	3	<b>3</b>

Objective/ Responsibility	Action	Lead	Deadline/ Meeting	Actual Completion	Update/Status
	Practice led single drug reviews.	Pharmacy/ Ray Pert	Ongoing		<p>Some progress was made with these during 2020/21, but less than previous years due to impact of COVID-19 on priorities. Further identification will take place over 2021/22.</p> <p>The loss of project support as diverted to Covid-19 related priorities has stalled further progress on this action.</p> <p>Agreed to close off and restart new action now a change in project support has been identified.</p>

Objective/ Responsibility	Action	Lead	Deadline/ Meeting	Actual Completion	Update/Status
Vigilance with regard to top 70 GIC medicines	Dr Jamieson/Jenna Murray will report quarterly on significant movement on spend within the top 70 GIC list.	Dr Scott Jamieson/ Jenna Murray	240821	Ongoing	This data continues to be reviewed with some improvements identified although Covid-19 has diverted resource for prescribing saving opportunities. Chronic pain and mental health remains a prominent area of increased cost.
Serial Prescribing	Practices to continue to review suitable patients with a view to move toward a figure of 40% of suitable patients on to serial prescriptions by March 2022.	All	Quarterly	Ongoing	Progress is being made. A steady increase in % CMS patient by list size, up 1% in previous quarter and up 3.5% compared to same period last year.
Strategic Prescribing Risk	Quarterly review of the Strategic Prescribing Risk noting controls in place and provision of additional assurance requirements.	All	Quarterly	Ongoing	This risk is now monitored regularly with the Angus prescribing management group. (Current risk score (with mitigation) 16, formerly 9)

Objective/ Responsibility	Action	Lead	Deadline/ Meeting	Actual Completion	Update/Status
	LTC/polypharmacy reviews.	Cluster Leads Dr Nico Grunenberg Deirdre Cameron	3103 21		The remobilisation plans for Tayside for long term conditions support GPs with prioritisation of polypharmacy and long term condition reviews. The Angus GP QI lead is supporting Angus practices with quality improvement in this area. Future proposals include GP clusters to each carry out one quality improvement activity in relation to prescribing annually.
	National Therapeutic Indicators.	Cluster Leads	3103 21		The national therapeutic indicators are increasingly reported on and their use promoted throughout various Angus HSCP forums.
Impact of non-medicines	Non-pharmacological pain pathway to be launched regionally. Local promotion and support of its use in therapy.	Dr Alison Clement	Ongoing		This has been launched and its use promoted through sharing in the primary care Covid-19 newsletter, addition of links within the NHST formulary and by encouraging cluster leads to promote.

Objective/ Responsibility	Action	Lead	Deadline/ Meeting	Actual Completion	Update/Status
	Care homes – improve governance with regard to catheter use and subsequent e-coli diagnosis and treatment. This will require collaborative working with both DNs and care home staff.	Michelle Logan Rena/Karen Fletcher	180820  27/4/21		Current indications are a reduction in community acquired e.coli bacteraemia recently in Angus. Standards are being developed to support frail elderly care in Angus with quality improvement planned. A proposal for nursing in care home standards will be taken to Angus Clinical Partnership Group in June 2021.  Dr Clement – Bladder scanner is excellent. Incontinence formularies are there.
HAI standards on infection prevention and control (delivery area 1)	Antimicrobial prescribing and resistance tracking	All/Dr Scott Jamieson	Ongoing		Clusters have the opportunity to review their prescribing data on antibiotic use. Angus continues to perform well in national indicators.